Two open label studies tested the effect of ALC in patients with neuropathy induced by paclitaxel and cisplatin

Covariates We matched our statistical models for the following covariates: age, sex, T2D complications (kidney, ophthalmic, neurological, and circulatory), comorbidities (alcohol-related disorders, nicotine dependence, hypertension, dyslipidemia, T2D, overweight/obesity, hypertensive disease, cerebrovascular disease, ischemic heart disease, chronic kidney disease, chronic lower respiratory disease, neoplasms, and systemic connective tissue disorders), lipid-lowering agents (HMG-CoA reductase inhibitors, ezetimibe, evolocumab, and alirocumab), antihypertensives (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, calcium-channel blockers, diuretics, and furosemide), anti-anginal or anti-ischemic agents (organic nitrates and ranolazine), heart failure medications (angiotensin receptor-neprilysin inhibitors, eplerenone, vericiguat, digitalis glycosides, SGLT2i, spironolactone, and ivabradine), antiplatelet drugs (aspirin, clopidogrel, ticagrelor, prasugrel, and cangrelor), hemoglobin A1c, and eGFR

As it is well established that subject compliance and retention are significantly reduced when a placebo condition is identified, the present design was utilized in which the placebo condition of the first two assessments served as the baseline condition, each subject serving as their own control
nice post
Dosage is based on your condition
The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient Yin-Yang theory and modern immunology